A 
17,240
+5.70%
Close of 9 Nov 2026, in KRW
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
At a glance
Figures in KRW, from our data supplier.
Revenue
₩4.71bn
FY2016FY2025
Net income
−₩17.91bn
FY2016FY2025
Free cash flow
−₩14.45bn
FY2016FY2025
Shareholders' equity
₩60.44bn
FY2016FY2025
Income statement
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₩4.71bn | ₩2.34bn | ₩2.88bn | ₩3.41bn | ₩3.02bn | ₩2.77bn | ₩14.38bn | ₩3.92bn | ₩3.53bn | ₩3.12bn |
| Research and development | ₩14.43bn | ₩13.39bn | ₩10.73bn | ₩8.69bn | ₩9.63bn | ₩5.86bn | ₩3.88bn | ₩2.37bn | ₩1.72bn | ₩1.99bn |
| Operating income | −₩17.64bn | −₩15.76bn | −₩12.40bn | −₩8.75bn | −₩10.23bn | −₩6.57bn | ₩4.28bn | −₩1.96bn | −₩1.54bn | −₩1.61bn |
| Net income | −₩17.91bn | −₩16.30bn | −₩12.90bn | −₩9.25bn | −₩10.24bn | −₩6.44bn | ₩2.57bn | −₩842.7m | −₩1.48bn | −₩1.60bn |
| Diluted earnings per share | -898.70 | -935.52 | -830.91 | -604.11 | -670.10 | -421.84 | 178.83 | -117.70 | -109.01 | -130.90 |
Balance sheet
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | ₩70.75bn | ₩48.18bn | ₩45.42bn | ₩54.06bn | ₩29.83bn | ₩40.13bn | ₩46.97bn | ₩28.70bn | ₩20.87bn | ₩16.01bn |
| Cash and short-term investments | — | ₩21.86bn | ₩17.50bn | ₩24.14bn | ₩10.27bn | ₩19.55bn | ₩28.44bn | ₩19.85bn | ₩15.83bn | ₩11.64bn |
| Total liabilities | ₩10.31bn | ₩18.78bn | ₩18.19bn | ₩17.46bn | ₩10.47bn | ₩10.80bn | ₩11.59bn | ₩10.01bn | ₩3.47bn | ₩4.03bn |
| Debt | — | ₩17.25bn | ₩12.60bn | ₩11.76bn | ₩7.09bn | ₩7.20bn | ₩7.03bn | ₩2.00bn | ₩2.00bn | ₩2.00bn |
| Shareholders' equity | ₩60.44bn | ₩29.41bn | ₩27.23bn | ₩36.60bn | ₩19.36bn | ₩29.33bn | ₩35.38bn | ₩18.70bn | ₩17.39bn | ₩11.98bn |
| Shares outstanding | 20m | 17m | 16m | 15m | 15m | 15m | 14m | 7m | 14m | 12m |
Cash flow
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | −₩13.83bn | −₩14.39bn | −₩9.48bn | −₩7.49bn | −₩8.64bn | −₩5.65bn | −₩449.9m | ₩3.71bn | −₩1.11bn | −₩204.9m |
| Capital spending | −₩617.6m | −₩167.5m | −₩49.8m | −₩75.6m | −₩505.4m | −₩3.44bn | −₩10.56bn | −₩2.36bn | −₩63.7m | −₩242.2m |
| Free cash flow | −₩14.45bn | −₩14.56bn | −₩9.53bn | −₩7.57bn | −₩9.15bn | −₩9.09bn | −₩11.01bn | ₩1.35bn | −₩1.18bn | −₩447.1m |
Latest quarters
By quarter end
| Jun 2026 | Mar 2026 | Dec 2025 | Sept 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sept 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₩1.68bn | ₩434.2m | ₩1.62bn | ₩1.57bn | ₩1.11bn | ₩412.6m | ₩709.9m | ₩797.9m |
| Operating income | −₩6.25bn | −₩3.06bn | −₩5.01bn | −₩3.54bn | −₩3.44bn | −₩5.75bn | −₩3.15bn | −₩3.35bn |
| Net income | −₩6.06bn | −₩2.78bn | −₩5.06bn | −₩3.52bn | −₩3.47bn | −₩5.98bn | −₩3.26bn | −₩3.43bn |
| Diluted earnings per share | -304.07 | -139.59 | -253.99 | -184.46 | -181.71 | -337.89 | -187.09 | -196.61 |
| Cash from operations | −₩6.05bn | −₩3.19bn | −₩2.22bn | −₩2.17bn | −₩3.01bn | −₩6.42bn | −₩14.39bn | −₩11.44bn |
| Capital spending | −₩27.0m | −₩25.0m | −₩155.0m | — | −₩23.0m | −₩438.0m | −₩167.0m | −₩164.0m |
| Free cash flow | −₩6.08bn | −₩3.22bn | −₩2.38bn | — | −₩3.03bn | −₩6.86bn | −₩14.56bn | −₩11.60bn |
| Total assets | ₩64.50bn | ₩68.43bn | ₩70.75bn | ₩38.50bn | ₩41.41bn | ₩32.96bn | ₩48.18bn | ₩33.03bn |
| Cash and short-term investments | — | — | — | — | — | ₩4.86bn | ₩21.86bn | ₩5.79bn |
| Debt | — | — | — | — | — | ₩7.08bn | ₩7.01bn | ₩7.04bn |
| Shareholders' equity | ₩53.07bn | ₩58.28bn | ₩60.44bn | ₩29.07bn | ₩32.37bn | ₩23.63bn | ₩29.41bn | ₩23.63bn |
Financial ratios
Data as of 29 Aug 2026
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | |
|---|---|---|---|---|---|---|---|---|
| Operating margin | -374.1% | -673.6% | -431.1% | -256.9% | -338.9% | -237.1% | — | — |
| Net margin | -379.9% | -696.7% | -448.5% | -271.7% | -339.2% | -232.6% | — | — |
| Return on equity | -29.6% | -55.4% | -47.4% | -25.3% | -52.9% | -22.0% | — | — |
| Return on assets | -25.3% | -33.8% | -28.4% | -17.1% | -34.3% | -16.1% | — | — |
| Free cash flow yield | — | — | — | — | — | — | — | 3.3% |
| Revenue growth | 101.5% | -18.7% | -15.5% | 12.9% | 8.9% | -80.7% | — | — |
| Earnings growth | 9.8% | 26.3% | 39.4% | -9.6% | 58.8% | -351.1% | — | — |
| Current ratio | 4.92x | 1.28x | 1.10x | 2.86x | 1.18x | 4.72x | — | — |
| Debt to equity | — | 0.24x | 0.26x | 0.32x | 0.10x | 0.17x | 0.14x | — |
| Equity ratio | 85.4% | 61.0% | 60.0% | 67.7% | 64.9% | 73.1% | — | — |
| Interest coverage | -40.20x | -17.51x | -9.18x | -17.87x | -57.23x | -34.76x | — | — |
| R&D as a share of sales | 306.1% | 572.4% | 373.1% | 255.2% | 318.9% | 211.4% | — | — |
Growth per year
Compound annual rate
| 3 years | 5 years | 10 years | |
|---|---|---|---|
| Revenue | 11.4% | 11.2% | 9.2% |
| Operating income | 26.3% | 21.8% | 19.0% |
| Net income | 24.6% | 22.7% | 6.2% |
Average margins
Over each period
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Operating margin | -473.5% | -409.0% | -373.0% | -163.5% |
| Net margin | -485.0% | -422.6% | -381.9% | -183.1% |
Valuation history
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Price to earnings | -47.3 | -15.1 | -17.8 | -21.2 | -26.4 | -86.5 | 112.1 | -172.7 | -301.4 |
| Price to sales | 179.6 | 105.2 | 80.0 | 57.6 | 89.6 | 201.2 | 20.0 | 37.1 | 126.5 |
Dividends and splits
Per share, in the currency the company pays
Paid for 0 years.
- 2-for-1 split · 16 Jul 2020
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.